For: | Xu LN, Wang X, Zou SQ. Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines. World J Gastroenterol 2008; 14(16): 2578-2581 [PMID: 18442209 DOI: 10.3748/wjg.14.2578] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v14/i16/2578.htm |
Number | Citing Articles |
1 |
Daniel H. Ahn, Milind Javle, Chul W. Ahn, Apurva Jain, Sameh Mikhail, Anne M. Noonan, Christina Wu, Rachna T. Shroff, James L. Chen, Tanios Bekaii‐Saab. Next‐generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer 2016; 122(23): 3657 doi: 10.1002/cncr.30247
|
2 |
Eric J. Grossman, J. Michael Millis. Liver transplantation for non-hepatocellular carcinoma malignancy: Indications, limitations, and analysis of the current literature. Liver Transplantation 2010; 16(8): 930 doi: 10.1002/lt.22106
|
3 |
Vikrant Rai, Chandra Boosani, Devendra Agrawal. The promising role of epigenetic mediators and microRNAs in the early diagnosis of cholangiocarcinoma (Review). World Academy of Sciences Journal 2019; doi: 10.3892/wasj.2019.18
|
4 |
Christian Mayr, Tobias Kiesslich, Sara Erber, Dino Bekric, Heidemarie Dobias, Marlena Beyreis, Markus Ritter, Tarkan Jäger, Bettina Neumayer, Paul Winkelmann, Eckhard Klieser, Daniel Neureiter. HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer. Cancers 2021; 13(15): 3862 doi: 10.3390/cancers13153862
|
5 |
Luca Maroni, Marco Marzioni. Diagnosis and Management of Cholangiocarcinoma. 2021; : 555 doi: 10.1007/978-3-030-70936-5_26
|
6 |
Junpei Yamaguchi, Motoko Sasaki, Yasunori Sato, Keita Itatsu, Kenichi Harada, Yoh Zen, Hiroko Ikeda, Yuji Nimura, Masato Nagino, Yasuni Nakanuma. Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma. Cancer Science 2010; 101(2): 355 doi: 10.1111/j.1349-7006.2009.01387.x
|
7 |
Huiling Wang, Caixia Li, Zhixiang Jian, Yingliang Ou, Jinrui Ou, Jin Q. Cheng. TGF-β1 Reduces miR-29a Expression to Promote Tumorigenicity and Metastasis of Cholangiocarcinoma by Targeting HDAC4. PLOS ONE 2015; 10(10): e0136703 doi: 10.1371/journal.pone.0136703
|
8 |
Xilin Du, Huadong Zhao, Li Zang, Nuan Song, Tao Yang, Rui Dong, Jikai Yin, Chengguo Wang, Jianguo Lu. Overexpression of Histone Deacetylase 2 Predicts Unfavorable Prognosis in Human Gallbladder Carcinoma. Pathology & Oncology Research 2013; 19(3): 397 doi: 10.1007/s12253-012-9592-y
|
9 |
Bing Wang, Rui Yang, Yue Wu, Hongbo Li, Zouxiao Hu, Yongjun Chen, Shengquan Zou. Sodium Valproate Inhibits the Growth of Human CholangiocarcinomaIn VitroandIn Vivo. Gastroenterology Research and Practice 2013; 2013: 1 doi: 10.1155/2013/374593
|
10 |
Richard L. Bennett, Alok Swaroop, Catalina Troche, Jonathan D. Licht. The Role of Nuclear Receptor–Binding SET Domain Family Histone Lysine Methyltransferases in Cancer. Cold Spring Harbor Perspectives in Medicine 2017; 7(6): a026708 doi: 10.1101/cshperspect.a026708
|
11 |
WEI YANG, XIAOYUAN WANG, WEI ZHENG, KEDONG LI, HAOFENG LIU, YUEMING SUN. Genetic and epigenetic alterations are involved in the regulation of TPM1 in cholangiocarcinoma. International Journal of Oncology 2013; 42(2): 690 doi: 10.3892/ijo.2012.1741
|
12 |
Dawoon E. Jung, Soo Been Park, Kahee Kim, Chanyang Kim, Si Young Song. CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-11094-3
|